Clinical characteristics and 28-day outcomes of sepsis associated with klebsiella pneumoniae carbapenemase-producing Enterobacterales: a single-center retrospective cohort study
摘要
Sepsis caused by carbapenemase-producing Enterobacterales, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing strains, is associated with high mortality and limited treatment options. However, data regarding dynamic organ dysfunction and prognostic factors in this population remain limited.
ObjectiveTo compare the clinical characteristics and outcomes of sepsis due to KPC-producing versus non-KPC-producing Enterobacterales and to identify independent predictors of 28-day mortality.
MethodsIn this single-center retrospective cohort study, 320 intensive care unit (ICU) patients with sepsis and microbiologically confirmed Enterobacterales infection (January-December 2024) were included. Patients were classified as KPC (n = 210) or non-KPC (n = 110) using the NG-Test CARBA 5 assay, with polymerase chain reaction (PCR) confirmation when available. The primary outcome was 28-day all-cause mortality from sepsis onset. Multivariable logistic and Cox regression analyses were performed.
ResultsThe KPC group had significantly higher 28-day mortality than the non-KPC group (35.2% vs. 23.6%, odds ratio [OR] = 1.77, 95% confidence interval [CI]: 1.04-3.00, P = 0.030). KPC infection remained independently associated with mortality after adjustment (adjusted OR [aOR] = 1.58, 95% CI: 1.02–2.44, P = 0.04). Additional independent risk factors included higher Day-1 Sequential Organ Failure Assessment (SOFA) score (aOR = 1.08), elevated lactate level (aOR = 1.12), and inadequate early antimicrobial therapy (aOR = 1.69; all P < 0.05). In the KPC subgroup, ΔSOFA, positive fluid balance, and low albumin levels were also associated with mortality.
ConclusionSepsis caused by KPC-producing Enterobacterales is associated with more severe organ dysfunction and increased short-term mortality. Early administration of appropriate antimicrobial therapy, along with optimized organ support and fluid management, may improve clinical outcomes.
Clinical trial numberNot applicable.